Like apoptosis, senescence can now be viewed as a here: in response to a ras oncogene, a cell may slow down its growth and sink into a state of prolonged dereflex that cells will activate in response to multiple stimuli. Apoptosis may be triggered by genomic damage, crepitude rather than lurch abruptly into total senescence. After limping along for years, even decades, one conflicting growth-regulatory signals, or death factors such as the Fas ligand. The exhaustion of allotted repliof its slowly proliferating descendants may succeed in knocking out one of the tumor suppressor genes that cative cycles or the inadvertant activation of an oncogene can trigger senescence. It is likely that yet other have been holding back growth. Only then can the rapid, sustained clonal expansion associated with transphysiologic signals will be found that are equally capable of triggering the senescence response.
formed cell populations begin.
Cancer and Immortality Cooperating Mutations
An oncogene-bearing, pre-malignant cell will need to This model also explains another longstanding puzzle in cancer cell biology. As mentioned above, in 1983, circumvent the senescence countermeasure erected by its own internal circuitry in order to advance its agenda researchers observed that primary cultures of embryonic cells resist transformation by a ras oncogene while of progressing toward a fully malignant state. How such a cell succeeds in subverting the senescence reponse immortalized cells are highly susceptible. On its surface, this observation made little sense: The refractory priis also revealed by Serrano et al. As is often the case these days, the mechanistic answers to questions like mary cells were still many replicative cycles away from exhausting their allotment of generational doublings. these come from examining the components of another clocking device-the cell cycle clock apparatus.
Why should their state of immortalization (or lack thereof) affect their short-term responsiveness to an After several days exposure to a ras oncogene, a cell will begin to make high levels of p16 and p53. p16, also introduced oncogene?
The answer appears to come from an examination of known as p16 INK4A , is a well-studied, specific inhibitor of the CDK4 and CDK6 cyclin-dependent kinases (CDKs) precisely how cultured cells achieve replicative immortality. They often do so by inactivating their p16 or p53 that operate during the G1 phase of the cell cycle. These kinases function to phosphorylate and thereby inactigenes (Whitaker et al., 1995) ; one or the other gene inactivation seems to be selected during extended pasvate the growth-suppressing activities of pRB, the retinoblastoma protein, as well as the related p107 and sage in culture. As an unintended side-product of such gene inactivations, immortalized cells also lose their prip130 proteins (Weinberg, 1995) . The actions of p53 are more far-reaching. Acting as a transcription factor, it mary defense mechanism against oncogene-induced transformation. The fact that cells use senescence as induces expression of another CDK inhibitor, p21, which antagonizes a spectrum of CDKs operating throughout a response to two unrelated provocations (oncogene transformation and excessive generational doublings) the cell cycle. (p53 may also mobilize other downstream growth-inhibitory effectors, not all of which have been means that selection for one phenotype (ability to double indefinitely) affects their responses to an unrelated stimelucidated) (Levine, 1997) .
These inductions of p16 and p53 proteins are far more ulus (oncogene activation). Collaborating Oncogenes than epiphenomena of senescence. They appear, instead, to be causally involved in triggering this state.
The above-cited work explains how an oncogene activation (ras) can cooperate with the inactivation of a tumor As Serrano et al. demonstrate, experimental inactivation of either encoding gene subverts the senescence resuppressor gene (p16 or p53) to achieve cell transformation. It also provides a compelling molecular explanation sponse of the cell. Now we realize the counter-countermeasure that asfor how two oncogenes can collaborate in cell transformation. For example, the ras oncogene is known to piring cancer cells will take to override ras-induced senescence: they will inactivate through mutation either collaborate with the adenovirus E1A, SV40 large T, or human papilloma virus E6 or E7 oncogenes to transform their p16 or p53 genes. Either change will do. Importantly, these gene inactivations occur frequently in sponprimary cells. (Land et al., 1983; Ruley, 1983 Ruley, , 1990 ). Three of these (E1A, large T, and E7) are known to distaneously arising tumors. A substantial body of evidence indicates that the p53 or p16 genes (or both) are mutated able pRB, the primary target of CDK4 and CDK6 phosphorylation. A wealth of biochemical evidence indicates in the vast majority of human tumors. (Hollstein et al., 1994; Hirama and Koeffler, 1995) .
that the disabling of pRB should result in a close phenocopy of p16 inactivation (Weinberg, 1995) . Two of these These observations provide a compelling mechanistic explanation of why cells need to mutate multiple genes oncogenes (large T and E6) antagonize p53; Serrano et al. would argue that this is equally effective in disabling in order to become fully transformed. In this instance, the first mutation, which activates ras, provides the cell senescence and rendering a cell susceptible to ras transformation. with the growth impetus required for sustained proliferation. The second mutation (inactivating either p16 or
In fact, ras activation and subsequent p53 inactivation figure prominently in the best-studied example of human p53) has no direct effect on cell proliferation per se. Instead, it serves to neutralize the cell's built-in antitumor progression-that resulting in colon carcinoma (Vogelstein and Kinzler, 1993) . Still, a rigorous proof of cancer defenses.
Still, one aspect of this scheme makes little sense: the relevance of the in vitro cell transformation models to tumorigenesis in vivo will require an additional piece if a cell shuts downs its growth immediately after ras oncogene activation, how will the opportunity to inactiof evidence-the demonstration that a ras oncogene arising spontaneously in a living tissue actually provokes vate its p16 or p53 genes ever arise? This conundrum is likely solved by a slight revision of the model depicted senescence, or at least a proliferative slowdown. Ruley, H.E. (1990 sponse-apoptosis. (Evan et. al., 1992) . Others sub- 971-976. sequently showed that the E1A oncogene, which is myc-like in some of its actions, also induces apoptosis (Debbas and White, 1993; Lowe and Ruley, 1993) . This apoptosis can be reversed by several means, among them, the introduction of ras oncogene (Lin et al., 1995) . Now we begin to see the symmetry in the design of the circuitry that programs the cell's defense mechanisms. ras and perhaps other similarly acting oncogenes induce a senescence which E1A can block. E1A induces an apoptosis which can be blocked by ras; ras appears also able to block myc-induced apoptosis (McKenna et al. 1996) . Hence, senescence and apoptosis represent the two alternative responses that cells mount in response to these two functionally complementary classes of oncogenes.
Unexplained by this are the precise physiologic and biochemical mechanisms by which the myc participates in these collaborations. Ostensibly, myc intervenes in the cell cycle clock machinery to prevent ras-induced senescence, but that is not yet shown experimentally. An important molecular clue is likely provided by the recent observation that the Myc protein can induce expression of the Cdc25A phosphatase, an important activator of G1 CDKs (Galaktionov et al., 1996) .
All this brings us a large step closer to realizing one of the major goals of current cancer research: rationalizing the complex, multi-step process of tumor progression in terms of the workings of the molecular machinery that operates inside cells to regulate their proliferation.
